Pacira BioSciences, Inc. (PCRX) stock news · rev $726.4M
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This PCRX news page leads with what Pacira BioSciences, Inc. filed — not a scraped headline mill.
No cached 8-K sentence for PCRX yet. We will not pad this page with generic market recap.
Latest reported PCRX revenue for 2025-12-31 was $726.4M. Net income was $7.0M. Revenue was up 3.6% from 2024-12-31 to 2025-12-31. PCRX currently screens at market cap $890.8M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the PCRX stock page; for the tape open the quote page.
PCRX stock news FAQ
What are PCRX's latest revenue and net income?
Latest cached Pacira BioSciences, Inc. (PCRX) revenue for Dec 31, 2025 was $726.4M. Net income was $7.0M. Statements: https://lician.com/financials/pcrx
How did PCRX revenue change from the prior cached period?
Cached Pacira BioSciences, Inc. (PCRX) revenue was up 3.6% from $701.0M (Dec 31, 2024) to $726.4M (Dec 31, 2025). Statements: https://lician.com/financials/pcrx
What is PCRX's market cap?
Pacira BioSciences, Inc. (PCRX) market cap is $890.8M on the latest cached fundamentals snapshot.
What kind of company is PCRX?
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Where is PCRX stock news listed?
Cached stock news for Pacira BioSciences, Inc. (PCRX) is listed at https://lician.com/news/pcrx. Filings: https://lician.com/sec/pcrx
Not investment advice.